Dapagliflozin
- Generic Name
- Dapagliflozin
- Brand Names
- Edistride, Farxiga, Forxiga, Qtern, Qternmet, Xigduo, Dapagliflozin Viatris
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25ClO6
- CAS Number
- 461432-26-8
- Unique Ingredient Identifier
- 1ULL0QJ8UC
- Background
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosur...
- Indication
Dapagliflozin is indicated as an adjunct treatment to improve glycemic control in adult patients with type 2 diabetes mellitus along with diet and exercise.For patients with chronic kidney disease at risk of progression, dapagliflozin in used to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and
...
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate, Hospitalization due to cardiac failure
- Associated Therapies
- -
Effects of Liraglutid, Dapagliflozin and Acarbose on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in Overweight/Obese T2DM Patients Controlled Inadequately With Metformin Monotherapy.
- Conditions
- Interventions
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2019-05-23
- Target Recruit Count
- 87
- Registration Number
- NCT03961659
- Locations
- 🇨🇳
at Division of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University, Nanjing, Jiangsu, China
Triple Therapy in T1DM
- Conditions
- Interventions
- First Posted Date
- 2019-04-02
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- State University of New York at Buffalo
- Target Recruit Count
- 114
- Registration Number
- NCT03899402
- Locations
- 🇺🇸
Diabetes and Endocrinology Research Center of WNY, Williamsville, New York, United States
DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction
- Conditions
- Interventions
- First Posted Date
- 2019-03-15
- Last Posted Date
- 2021-05-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 313
- Registration Number
- NCT03877237
- Locations
- 🇸🇪
Research Site, Umeå, Sweden
DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction
- Conditions
- Interventions
- First Posted Date
- 2019-03-15
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 504
- Registration Number
- NCT03877224
- Locations
- 🇸🇪
Research Site, Umeå, Sweden
Left Ventricular Functional Changes of Uncontrolled Diabetes by Dapagliflozin Treatment Trial
- Conditions
- Interventions
- First Posted Date
- 2019-03-12
- Last Posted Date
- 2023-03-22
- Lead Sponsor
- Mackay Memorial Hospital
- Target Recruit Count
- 76
- Registration Number
- NCT03871621
- Locations
- 🇨🇳
Mackay Memorial Hospital, Taipei, Taiwan
Dapagliflozin In Alzheimer's Disease
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Jeff Burns, MD
- Target Recruit Count
- 46
- Registration Number
- NCT03801642
- Locations
- 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States
Effects of SGLT-2 Inhibition on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI in Patients With DM2
- Conditions
- Interventions
- First Posted Date
- 2018-12-20
- Last Posted Date
- 2023-12-29
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 62
- Registration Number
- NCT03782259
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2018-12-04
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Travere Therapeutics, Inc.
- Target Recruit Count
- 406
- Registration Number
- NCT03762850
- Locations
- 🇬🇧
Travere Investigational Site, London, United Kingdom
Head-to-head Comparison of Empagliflozin and Dapagliflozin
- First Posted Date
- 2018-11-21
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Chungbuk National University Hospital
- Target Recruit Count
- 600
- Registration Number
- NCT03748810
- Locations
- 🇰🇷
Chungbuk National University Hospital, Cheonju, Chungcheongbuk-do, Korea, Republic of
Dapagliflozin Efficacy and Action in NASH
- First Posted Date
- 2018-10-29
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 154
- Registration Number
- NCT03723252
- Locations
- 🇨🇳
Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.